- ►annals.org [PDF] AMF Yee, MB Pochapin - Annals of internal medicine, 2001 - Am Coll Physicians Measurements: Clinical response of enteropathic and myo- pathic symptoms and
serum albumin level. Results: Enteropathic and myopathic symptoms resolved after
infliximab therapy, and the serum albumin level also improved. However, the ... Cited by 150 - Related articles - All 6 versions
RP Baughman, EE Lower - Sarcoidosis, vasculitis, and diffuse lung diseases: …, 2001 - ncbi.nlm.nih.gov BACKGROUND AND AIM OF WORK: Tumor necrosis factor-alpha (TNF-alpha) appears to
be an important cytokine in the inflammation of sarcoidosis. Infliximab is a
chimeric monoclonal antibody which specifically inhibits TNF-alpha. We ... Cited by 164 - Related articles - BL Direct
JA Pettersen, DW Zochodne, RB Bell, L Martin … - Neurology, 2002 - AAN Enterprises 2002;59;1660 Neurology JA Pettersen, DW Zochodne, RB Bell, L. Martin and MD Hill
Refractory neurosarcoidosis responding to infliximab ... This information is
current as of October 15, 2009 ... All rights reserved. Print ISSN: ... Cited by 60 - Related articles - BL Direct - All 4 versions
- ►chestpubs.org JP Utz, AH Limper, S Kalra, U Specks, JP … - Chest, 2003 - chestjournal.chestpubs.org Background: Tumor necrosis factor (TNF)-α is produced by macrophages and other
cells, and is believed to participate in granulomatous inflammation. Targeted
antagonism of TNF-α has been proposed as a novel treatment strategy for ... Cited by 139 - Related articles - BL Direct - All 5 versions
P Zabel, P Entzian, K Dalhoff, M Schlaak - American journal of respiratory and critical care …, 1997 - Am Thoracic Soc The optimal therapy for sarcoidosis remains unclear. Most patients show a
short-term response to corticosteroid therapy, but they have to face the risk of
significant side effects. Because tumor necrosis factor alpha (TNF) plays a ... Cited by 120 - Related articles - BL Direct - All 5 versions
- ►chestpubs.org SD Roberts, DS Wilkes, RA Burgett, KS Knox - Chest, 2003 - chestjournal.chestpubs.org Despite aggressive treatment with conventional therapy, sarcoidosis may be
progressive and debilitating. Tumor necrosis factor (TNF)-α is critical in the
genesis and maintenance of granulomatous inflammation. Agents developed to ... Cited by 69 - Related articles - BL Direct - All 5 versions
RP Baughman, MA Judson, AS Teirstein, DR … - Chest, 2002 - chestjournal.chestpubs.org * From the Department of Internal Medicine (Drs. Baughman and Lower), University
of Cincinnati Medical Center, Cincinnati, OH; Division of Pulmonary and Critical
Care Medicine (Dr. Judson), Medical University of South Carolina, ... Cited by 106 - Related articles - BL Direct - All 6 versions
RP Baughman, SA Strohofer, J Buchsbaum, … - The Journal of laboratory and clinical medicine, 1990 - ncbi.nlm.nih.gov Tumor necrosis factor (TNF) is a monokine released by macrophages and is
important in the inflammatory response. We compared the spontaneous release of
TNF by alveolar macrophages (AMs) from patients with symptomatic pulmonary ... Cited by 98 - Related articles
- ►171.66.122.149 M Baltzan, S Mehta, TH Kirkham, MG COSIO - American journal of respiratory and critical care …, 1999 - 171.66.122.149 Sarcoidosis may cause severe ventilatory impairment requiring corticosteroid
treatment. Chloroquine (CQ) can be an effective treatment for lung sarcoidosis
with few side effects, but has not been accepted as standard therapy. We ... Cited by 68 - Related articles - BL Direct - All 8 versions
